JMP Securities Thinks Flex Pharma’s Stock is Going to Recover

By Jason Carr

In a report released today, Michael King from JMP Securities reiterated a Buy rating on Flex Pharma (NASDAQ: FLKS). The company’s shares opened today at $5.05, close to its 52-week low of $4.55.

According to, King is ranked 0 out of 5 stars with an average return of -12.0% and a 28.8% success rate. King covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Syndax Pharmaceuticals Inc, and Karyopharm Therapeutics.

Flex Pharma has an analyst consensus of Strong Buy.

The company has a one year high of $13.97 and a one year low of $4.55. Currently, Flex Pharma has an average volume of 66.98K.

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FLKS in relation to earlier this year. Most recently, in July 2016, John Sculley, a Director at FLKS bought 4,709 shares for a total of $56,131.

Flex Pharma, Inc. operates as a biotechnology company, which engages in developing treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions. The company was founded by Christoph Westphal and Jennifer M. Cermak on February 26, 2014 and is headquartered in Boston, MA.